Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UnitedHealth’s i3 Unit Tapped By FDA To Provide Postmarketing Surveillance

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is close to reaching additional deals with manufacturers for use of its i3 Aperio postmarketing surveillance drug registry.

You may also be interested in...



Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry

UnitedHealth subsidiary Ingenix announces 14 new products to be included in the Aperio postmarketing surveillance registry. By year-end, the company expects the registry will include all the recent NMEs used by more than 1,000 UnitedHealth patients.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

Topics

UsernamePublicRestriction

Register

PS062967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel